Next‑Generation Tau Marker Capturing the Core of Alzheimer’s Disease

Product Overview

This kit is an ELISA assay capable of highly sensitive measurement of the blood biomarker pTau217, which reflects tau abnormalities in Alzheimer’s disease.
pTau217 is closely associated with Aβ accumulation and is recognized as a highly specific indicator of Alzheimer’s pathology.
 

Features

  • High‑sensitivity measurement
    Achieves stable detection performance even in low‑concentration ranges
  • Highly reproducible assay system
    Enables reliable data acquisition for research use
  • Simple protocol
    Compatible with existing ELISA environments

Position within the ATN Framework

pTau217 is the representative biomarker for “T (Tau)” within the ATN framework, the international standard for Alzheimer’s disease diagnosis.
Through this kit, we contribute to enabling integrated evaluation based on the ATN framework.
 

Value for Research and Drug Discovery

pTau217 plays an important role in:

  • Early detection of Alzheimer’s disease
  • Highly disease‑specific evaluation
  • Validation of drug discovery targets
     

➡ A marker with potential applicability from research use to clinical implementation
 

Integration with KI‑ZA‑SHI

Through integration with the fully automated ELISA system “KI‑ZA‑SHI”, this kit enables:

  • Automated measurement
  • High‑throughput processing
  • Standardized data acquisition


➡ Evolution from manual workflows to a platform‑based approach

全自動ELISA装置 KI-ZA-SHI
拡大
全自動ELISA装置 KI-ZA-SHI

Business Significance (IR Highlights)

The pTau217 kit is a strategic core product that supports:

  • Entry into the high‑value biomarker domain
  • Creation of sustained demand for reagents
  • Establishment of a pathway leading to the adoption of KI‑ZA‑SHI
     

Tau markers that capture the “core” of Alzheimer's disease